

# CCT129202

Catalog No: tcsc0206



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

942947-93-5

**Formula:**

$C_{23}H_{25}ClN_8OS$

**Pathway:**

Cell Cycle/DNA Damage;Epigenetics

**Target:**

Aurora Kinase;Aurora Kinase

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

497.02

## Product Description


CCT 137690 is an **aurora** kinase inhibitor with **IC<sub>50</sub>**s of 42, 198, and 227 nM for aurora A, B and C, respectively.

IC50 & Target: IC50: 142 nM (Aurora A), 198 nM (Aurora B), 227 nM (Aurora C)<sup>[1]</sup>

Ki: 49.8 nM (Aurora A)<sup>[1]</sup>

**In Vitro:** CCT129202 causes the accumulation of human tumor cells with 4N DNA content, leading to apoptosis. CCT129202 is found to induce apoptosis with GI<sub>50</sub> values that ranges between 0.08 and 1.7 μM. CCT129202-treated human tumor cells shows a delay in mitosis, abrogation of nocodazole-induced mitotic arrest, and spindle defects. CCT129202 Causes p21Up-regulation, Rb Hypophosphorylation, and H2F-DependentTK1Down-regulation<sup>[1]</sup>.

**In Vivo:** Growth of HCT116 xenografts in nude mice is inhibited after i.p. administration of CCT129202. p21, the cyclin-dependent kinase inhibitor, is induced by CCT129202. Up-regulation of p21 by CCT129202 in HCT116 cells led to Rb hypophosphorylation and E2F inhibition, contributing to a decrease in thymidine kinase 1 transcription<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!